亿万富翁投资者增加了维京药剂业的股权,而维京药剂业是一家开发减重药品的预发收入生物制药公司。 Billionaire investors increase stakes in Viking Therapeutics, a pre-revenue biopharma firm developing weight-loss drugs.
亿万富翁投资者 Jeff Yass 和 Israel Englander 正在增持 Viking Therapeutics 的股份，这是一家开发体重管理药物的生物制药公司。 Billionaire investors Jeff Yass and Israel Englander are increasing their stakes in Viking Therapeutics, a biopharma firm developing weight management drugs. 它的候选物VK2735,是双GLP-1和GIP受体激动剂,在试验中显示出有前途的减肥结果. Its candidate VK2735, a dual GLP-1 and GIP receptor agonist, showed promising weight loss results in trials. 在规划第3阶段试验时,该公司还探讨肝脏条件的VK2809。 While planning phase 3 trials, the company also explores VK2809 for liver conditions. 然而,由于还没有核准产品,该股票构成风险,适合高风险投资者。 However, with no approved products yet, the stock poses risks and is suited for high-risk investors.